

Abstract

The invention relates to a pharmaceutical formulation of the crystalline sodium salt of 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (telmisartan), and to processes for the preparation thereof.